Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (21-30 of 140) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|February 26, 2013
First-line treatment of indolent lymphoma: axing CHOP?Caron A Jacobson, Arnold S Freedman
Seminars in Hematology|January 10, 2024
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023Christine E Ryan, Caron A Jacobson
Blood|July 28, 2022
German CARs keeping paceEli P Darnell, Caron A Jacobson
Current Hematologic Malignancy Reports|March 21, 2016
Is There a Best Initial Treatment for a New Patient With Low Grade Follicular LymphomaCaron A Jacobson, Arnold S Freedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
One size does not fit all in follicular lymphomaCaron A Jacobson, Arnold S Freedman
Blood Advances|November 24, 2020
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomasCaron A Jacobson, Marcela V Maus
Blood Advances|January 23, 2024
Checkpoints: roadblocks or repairs for the CAR-T journey?Jennifer L Crombie, Caron A Jacobson
European Journal of Cancer (Oxford, England : 1990)|April 14, 2020
Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphomaRoch Houot, Philippe Armand, Caron A Jacobson
The Oncologist|October 6, 2019
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community OncologistCaron A Jacobson, Umar Farooq, Armin Ghobadi
Expert Opinion on Biological Therapy|July 26, 2019
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor productsBradley D Hunter, Michael Rogalski, Caron A Jacobson
Pageof 14

Showing results (21-30 of 140) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|February 26, 2013
First-line treatment of indolent lymphoma: axing CHOP?Caron A Jacobson, Arnold S Freedman
Seminars in Hematology|January 10, 2024
Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023Christine E Ryan, Caron A Jacobson
Blood|July 28, 2022
German CARs keeping paceEli P Darnell, Caron A Jacobson
Current Hematologic Malignancy Reports|March 21, 2016
Is There a Best Initial Treatment for a New Patient With Low Grade Follicular LymphomaCaron A Jacobson, Arnold S Freedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2013
One size does not fit all in follicular lymphomaCaron A Jacobson, Arnold S Freedman
Blood Advances|November 24, 2020
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomasCaron A Jacobson, Marcela V Maus
Blood Advances|January 23, 2024
Checkpoints: roadblocks or repairs for the CAR-T journey?Jennifer L Crombie, Caron A Jacobson
European Journal of Cancer (Oxford, England : 1990)|April 14, 2020
Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphomaRoch Houot, Philippe Armand, Caron A Jacobson
The Oncologist|October 6, 2019
Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community OncologistCaron A Jacobson, Umar Farooq, Armin Ghobadi
Expert Opinion on Biological Therapy|July 26, 2019
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor productsBradley D Hunter, Michael Rogalski, Caron A Jacobson
Pageof 14